BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wright RD, Bannerman F, Beresford MW, Oni L. A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy. BMC Nephrol 2020;21:245. [PMID: 32605540 DOI: 10.1186/s12882-020-01888-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Mejía-Vilet JM, Ayoub I. The Use of Glucocorticoids in Lupus Nephritis: New Pathways for an Old Drug. Front Med (Lausanne) 2021;8:622225. [PMID: 33665199 DOI: 10.3389/fmed.2021.622225] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Kim MJ, Lee H, Kim YH, Jin SY, Kim HJ, Oh D, Jeon JS. Eculizumab therapy on a patient with co-existent lupus nephritis and C3 mutation-related atypical haemolytic uremic syndrome: a case report. BMC Nephrol 2021;22:86. [PMID: 33691638 DOI: 10.1186/s12882-021-02293-2] [Reference Citation Analysis]
3 Li NL, Birmingham DJ, Rovin BH. Expanding the Role of Complement Therapies: The Case for Lupus Nephritis. J Clin Med 2021;10:626. [PMID: 33562189 DOI: 10.3390/jcm10040626] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Fernandez-Ruiz R, Blank RB, Wu M, Belmont HM. C3 glomerulonephritis and systemic lupus erythematosus: A report of a patient treated with eculizumab and review of the literature. Lupus 2021;:9612033211027938. [PMID: 34192954 DOI: 10.1177/09612033211027938] [Reference Citation Analysis]
5 Satyam A, Hisada R, Bhargava R, Tsokos MG, Tsokos GC. Intertwined pathways of complement activation command the pathogenesis of lupus nephritis. Transl Res 2022:S1931-5244(22)00048-2. [PMID: 35296451 DOI: 10.1016/j.trsl.2022.03.005] [Reference Citation Analysis]
6 Cantarelli C, Leventhal J, Cravedi P. Complement in Lupus: Biomarker, Therapeutic Target, or a Little Bit of Both? Kidney Int Rep 2021;6:2031-2. [PMID: 34386652 DOI: 10.1016/j.ekir.2021.06.016] [Reference Citation Analysis]
7 Harley ITW, Sawalha AH. Systemic lupus erythematosus as a genetic disease. Clin Immunol 2022;:108953. [PMID: 35149194 DOI: 10.1016/j.clim.2022.108953] [Reference Citation Analysis]
8 Boesen EI, Kakalij RM. Autoimmune-mediated renal disease and hypertension. Clin Sci (Lond) 2021;135:2165-96. [PMID: 34533582 DOI: 10.1042/CS20200955] [Reference Citation Analysis]
9 Weinstein A, Alexander RV, Zack DJ. A Review of Complement Activation in SLE. Curr Rheumatol Rep 2021;23:16. [PMID: 33569681 DOI: 10.1007/s11926-021-00984-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Soybilgic A. Biologic Agents and Other Emerging Therapies for Childhood SLE. Pediatr Ann 2022;51. [DOI: 10.3928/19382359-20220118-01] [Reference Citation Analysis]
11 Fernandez-ruiz R, Belmont HM. The role of anti-complement therapy in lupus nephritis. Translational Research 2022. [DOI: 10.1016/j.trsl.2022.02.001] [Reference Citation Analysis]
12 Ning X, Wang W, Jin H, Fang W. Low-Density Granulocytes in Immune-Mediated Inflammatory Diseases. Journal of Immunology Research 2022;2022:1-11. [DOI: 10.1155/2022/1622160] [Reference Citation Analysis]
13 Martis N, Jamme M, Bagnis-Isnard C, Pouteil-Noble C, Presne C, Vigneau C, Grangé S, Burtey S, Coindre JP, Wynckel A, Hamidou MA, Kanouni T, Azoulay E, Hié M, Chauveau D, Veyradier A, Rondeau E, Coppo P; French Reference Centre for Thrombotic Microangiopathies. Systemic autoimmune disorders associated with thrombotic microangiopathy: A cross-sectional analysis from the French National TMA registry: Systemic autoimmune disease-associated TMA. Eur J Intern Med 2021:S0953-6205(21)00199-0. [PMID: 34175183 DOI: 10.1016/j.ejim.2021.05.040] [Reference Citation Analysis]